Clinical trial · no report yet · Phase 2
BBOpCo
Botensilimab and Balstilimab Optimization in Colorectal Cancer
- NCT06268015 ↗
- Active, not recruiting
- Nicholas DeVito, MD
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 4 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Botensilimab; Balstilimab; Oxaliplatin; Leucovorin; Fluorouracil; Bevacizumab; Panitumumab
- Arms
- Treatment · Experimental
- Enrollment
- 16
- Primary outcomes
- Disease control rate based on iRECIST at second restaging scan
- Proportion of subjects with a best overall response of complete response or partial response according to iRECIST
- Sponsor
- Nicholas DeVito, MD with Gateway for Cancer Research, Agenus Inc.
- Start
- Nov 18, 2024
- Primary completion
- Jul 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06268015 · updated Feb 5, 2026